GlycoMimetics (NASDAQ: GLYC)
GlycoMimetics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
GlycoMimetics Company Info
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
News & Analysis
Why GlycoMimetics Is Tumbling 19.2% Today
Despite good news about its lead drug, investors are rushing for the exits.
Here's Why GlycoMimetics Could Become a Takeover Target
A wholly owned cancer drug could eventually reshape an important indication, and a new sickle-cell disease drug could be heading to the FDA as soon as next year.
Here's Why GlycoMimetics Is Soaring 24.3% Higher Today
Updated data that was presented at a key blood conference is exciting investors.
Why GlycoMimetics Is Tumbling 13.4% Today
New data from a trial evaluating one of its most promising drug candidates failed to impress investors.
Here's Why GlycoMimetics Rose as Much as 21% Today
The stock received yet another piece of good news this month -- this time, from Europe.
Why GlycoMimetics Is Ripping 19% Higher Today
Optimism over a mid-stage leukemia drug in development is causing shares to climb this week.
Valuation
Earnings Transcripts
GlycoMimetics (GLYC) Q2 2022 Earnings Call Transcript
GLYC earnings call for the period ending June 30, 2022.
GlycoMimetics (GLYC) Q1 2022 Earnings Call Transcript
GLYC earnings call for the period ending March 31, 2022.
GlycoMimetics (GLYC) Q4 2021 Earnings Call Transcript
GLYC earnings call for the period ending December 31, 2021.
GlycoMimetics, inc (GLYC) Q3 2021 Earnings Call Transcript
GLYC earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.